Company Overview and News

50
HRTX / Heron Therapeutics, Inc. null

9h sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]4>7!E+UA/8FIE8W0O0V]L;W)3 M<&%C92]$979I8V5'
HRTX

50
HRTX / Heron Therapeutics, Inc. null

9h sec.gov
CORRESP July 30, 2018 VIA EDGAR Andri Carpenter Keira Nakada
HRTX

50
HRTX / Heron Therapeutics, Inc. null

9h sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$Y M-S O3R [email protected],C
HRTX

79
Deciphera Pharmaceuticals: Will This ASCO Winner Repeat At ESMO?

2018-09-20 seekingalpha
The valuation gap with larger competitor Blueprint Medicines appears enticing, even after the latter's recent decline.
DCPH TSRO SHPG BPMC AMGN MRK SPPI AGIO HRTX PFE GSK

52
Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer

2018-09-18 globenewswire
WALTHAM, Mass., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has appointed Daniel C. Martin as Chief Commercial Officer. In this newly created role, Mr. Martin will be responsible for establishing the global strategy and leading the commercial organization at Deciphera.
DCPH HRTX

50
Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options

2018-09-14 zacks
Investors in Heron Therapeutics, Inc. (HRTX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $55.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
CY HRTX

151
Small Caps Are Rising, Biotechs Can't Be Far Behind

2018-09-05 seekingalpha - 9
While much attention is being riveted on the S&P 500's new all-time high eclipsing the January one, small caps accomplished that in May.
VRTX ECYT VSTM TRXC VKTX ENL CVS LGNDZ RGNX IMMU BIIB LGNYZ REGI HRTX NVTA NBIX ARWR SRPT ICPT VKTXW XLRN FNKO MRTX LGNZZ LGND NVS HEAR LGNXZ NTRA UNH PFE ENDP

109
10 Smart Money Stocks to Buy for the Rest of the Year

2018-08-31 investorplace - 5
As we head into the later months of 2018, here are some of the best smart money stocks to buy that will finish out 2018 in style.
WFCNP DB TEVA TEVVF NFLX ADBE ALXN AMAT HRTX CBS WFC CBS.A NBIX CBS.WD BABA EXPE TEVJF MU CPV UNH

50
Heron's Way Ahead: Is There Further Upside?

2018-08-28 seekingalpha
It has two products in the market and one in late stages of the approval process.
HRTX

50
HRTX / Heron Therapeutics, Inc. / HENDERSON GROUP PLC - JANUS HENDERSON GROUP PLC OWNS 7.3% HERON (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: HERON THERAPEUTICS, INC. Title of Class of Securities: Common Stock CUSIP Number: 427746102 Date of Event Which Requires Filing of this Statement: 7/31/2018 Check the appropriate box to designate the rule pursuant to which this Schedule is filed.
HRTX

50
HRTX / Heron Therapeutics, Inc. / HENDERSON GROUP PLC - JANUS HENDERSON GROUP PLC OWNS 7.3% HERON (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: HERON THERAPEUTICS, INC. Title of Class of Securities: Common Stock CUSIP Number: 427746102 Date of Event Which Requires Filing of this Statement: 7/31/2018 Check the appropriate box to designate the rule pursuant to which this Schedule is filed.
HRTX

63
Liquidia IPO: Phase 3 Clinical Stage That Interested The Bill Gates Foundation

2018-08-08 seekingalpha - 2
Liquidia Technologies, Inc. is a biopharmaceutical company developing products for the treatment of pulmonary arterial hypertension and local postoperative pain.
GLAXF PCRX GSK HRTX GSK DRRX LQDA

50
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Heron Therapeutics (HRTX - Free Report) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items.
HRTX

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to HRTX / Heron Therapeutics, Inc. on message board site Silicon Investor.

HRTX Heron Therapeutics Inc HRTX Heron Therapeutics Inc HRTX Heron Therapeutics Inc
CUSIP: 427746102